PG vs RXRX · P/E 25, rev $84.28B vs rev $58.8M
Procter & Gamble Company (PG) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Procter & Gamble Company (PG) is a household & personal products company listed on US. It is led by Jon Moeller.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported PG revenue for 2025-06-30 was $84.28B. Net income was $15.97B. PG currently screens at market cap $373.53B and trailing P/E 25.3.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
PG currently screens at market cap $373.53B and trailing P/E 25.3. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the PG and RXRX stock pages for the full models.
Not investment advice.